The Filing Desk

AbbVie vs Johnson & Johnson

AbbVie ABBV · Johnson & Johnson JNJ · Health Care

Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, 1.5 times AbbVie's $61.2 billion in fiscal 2025. AbbVie's revenue grew 8.6% in its latest year, and Johnson & Johnson's grew 6.0%. Free cash flow was $17.8 billion at AbbVie and $19.7 billion at Johnson & Johnson. Their fiscal years end in different months (December 31 and December 28), so the periods don't line up exactly.

Side by side

AbbVieJohnson & Johnson
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 28, 2025
Revenue$61.2B$94.2B
Revenue growth8.6%6.0%
Revenue growth a year, last 5 years6.0%2.7%
Gross margin70.2%67.9%
Operating margin24.6%—
Net margin6.9%28.5%
Free cash flow$17.8B$19.7B
Free cash flow margin29.1%20.9%
Return on capital15.7%28.6%
Net debt to EBITDA2.7x0.7x
Dividends and buybacks$12.6B$18.3B
Change in diluted share count0.0%0.0%
Last close$283.54$267.14
P/E at the last close48.8×40.5×
Insider trades, last 12 monthssold $30.8 millionbought $257,688, sold $154.4 million
Piotroski F-score7 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbbVieJohnson & Johnson
Operating margin
Percent of revenue
AbbVieJohnson & Johnson
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbVieJohnson & Johnson

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbbVie and Johnson & Johnson pages.